ID: h-26353f7f59
Hypothesis
Temporal order is subtype-specific rather than universal
The most defensible synthesis is that AD contains at least two trajectory classes: an amyloid-clearance/endosomal class and a trophic-transport/cholinergic-vulnerability class.
EvidencePending (0%)📖 7 cit🗣 1 debates✓ 7 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
The most defensible synthesis is that AD contains at least two trajectory classes: an amyloid-clearance/endosomal class and a trophic-transport/cholinergic-vulnerability class. This is less a single mechanism than a framework that can reconcile heterogeneous human biomarker sequences and guide stratified trials.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["NTRK1/TrkA Receptor<br/>Neurotrophin Tyrosine Kinase"]
B["NGF Binding<br/>Dimerization and Autophosphorylation"]
C["PI3K/AKT Pathway<br/>Survival Signal Cascade"]
D["MAPK/ERK Pathway<br/>Neuronal Differentiation"]
E["PLCgamma1 Activation<br/>Calcium Signaling Cascade"]
F["TrkA Internalization<br/>Endosomal Signaling"]
G["Sustained AKT Signaling<br/>Pro-Survival Outcome"]
H["Tau Phosphorylation<br/>ERK-Mediated GSK3B"]
I["Neuronal Apoptosis<br/>Survival Signal Loss"]
A --> B
B --> C
B --> D
B --> E
C --> F
F --> G
D --> H
G -->|"blocks"| I
H -.->|"contributes"| I
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style I fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix7 supports2 contradicts
Supports
Multimodal human biomarkers now support trajectory stratification using amyloid, tau, APOE, basal forebrain, and locus coeruleus measures.
Supports
Early cholinergic imaging and basal forebrain structural readouts provide a practical axis for testing non-identical prodromal paths.
Supports
ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.
Supports
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies.
Supports
APOE deficiency inhibits amyloid-facilitated (A) tau pathology (T) and neurodegeneration (N), halting progressive ATN pathology in a preclinical model.
Supports
Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease.
Supports
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised.
Contradicts
Subtype formulations can become post hoc and unfalsifiable unless classes are preregistered and replicated across independent cohorts.
Contradicts
Apparent classes may reflect measurement thresholds, staging, or co-pathology rather than true discrete biology.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — APOE
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for APOE, SORL1, NTRK1, BIN1, PICALM from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for APOE, SORL1, NTRK1, BIN1, PICALM.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.8%
Volatility
Low
0.0072
Events (7d)
2
Price History
▼18.5%💾 Resource Usage
LLM Tokens
19,162
$0.0575
Total Cost
$0.0575
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF late-onset AD cases are stratified by APOE4/SORL1 burden versus NTRK1/cholinergic expression markers at baseline, THEN the amyloid-clearance/endosomal subtype will show CSF Aβ42 abnormalities prece | At least 35% of AD cases will cluster into each of two distinct temporal biomarker orderings, with <10% showing intermediate/universal ordering patterns | — no observation — | pending | 0.55 |
| IF AD cases are stratified into amyloid-clearance/endosomal versus trophic-transport subtypes using the two-class framework, THEN anti-amyloid immunotherapy (anti-Aβ monoclonal antibodies) will demons | Significant treatment-by-subtype interaction (p<0.01) with opposite directional effects matching subtype mechanism predictions | — no observation — | pending | 0.45 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF late-onset AD cases are stratified by APOE4/SORL1 burden versus NTRK1/cholinergic expression markers at baseline, THEN the amyloid-clearance/endosomal subtype will show CSF Aβ42 abnormalities preceding tau phosphorylation by ≥2 years while the trophic-transport/cholinergic-vulnerability subtype w
Predicted outcome: At least 35% of AD cases will cluster into each of two distinct temporal biomarker orderings, with <10% showing intermediate/universal ordering patter
Falsification: All AD cases exhibit the same universal temporal ordering regardless of genetic/chemical stratification, or one subtype comprises <15% of the cohort
pendingconf 45%
IF AD cases are stratified into amyloid-clearance/endosomal versus trophic-transport subtypes using the two-class framework, THEN anti-amyloid immunotherapy (anti-Aβ monoclonal antibodies) will demonstrate ≥40% slower clinical decline in the amyloid-clearance subtype compared to the trophic-transpor
Predicted outcome: Significant treatment-by-subtype interaction (p<0.01) with opposite directional effects matching subtype mechanism predictions
Falsification: No significant treatment-by-subtype interaction (p>0.05) or uniform treatment response across both subtypes
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.